| - GSK enters patent settlement with Genentech regarding ofatumumab - Patents relate to recombinant antibody production - Financial details of settlement not disclosed COPENHAGEN, Denmark, March 26, 2012 (GLOBE NEWSWIRE) -- Genmab A/S (Copenhagen:GEN) announced today that GlaxoSmithKline (GSK) has agreed a settlement with Genentech Inc. and City of Hope (a California not-for-profit organization) concerning two U.S. patents that relate to recombinant antibody production for ofatumumab. GSK is Genm...continued GNMSF GNMSY |
Monday, March 26, 2012
Genmab Announces Patent Settlement Agreement for Ofatumumab
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment